| I-001 Noha Abdelgawad Pharmacokinetic Modelling of Rifampicin, Isoniazid, Pyrazinamide, and Linezolid in Central Nervous System: Insights from a Rabbit Model of Tuberculosis Meningitis Wednesday 10:20-11:50 |
| I-011 Arkadiusz Adamiszak Do critically ill patients undergoing continuous renal replacement therapy require ceftaroline dosage adjustments? Ceftaroline PopPK model and dosage simulations with probability of target attainment analysis based on retrospective data. Wednesday 10:20-11:50 |
| I-013 Romain Aubry Translational PKPD modelling of ceftazidime/avibactam for treatment of carbapenemase-producing Klebsiella pneumoniae in the persistently neutropenic rabbit pneumonia model Wednesday 10:20-11:50 |
| I-015 Salma Bahnasawy Applying PKPD modelling to evaluate the impact of plasma proteins in time-kill experiments; does the protein binding matter? Wednesday 10:20-11:50 |
| I-043 Nils Bundgaard Model informed dose projection for SAB-176 using a joint time-to-event modeling approach in high-risk (HR) patients infected with Influenza Wednesday 10:20-11:50 |
| I-044 Nils Bundgaard Framework for Polyclonal Antibody Drug Development: Integrating Trial Data and Literature Models Wednesday 10:20-11:50 |
| I-048 Jose Miguel Calderin Miranda Population pharmacokinetic analysis of isoniazid in plasma and cerebrospinal fluid from adults with HIV-associated tuberculosis meningitis Wednesday 10:20-11:50 |
| I-068 Emmanuelle Comets Modelling the dynamics of bacterial colonisation in a murine model of Urinary Tract Infections Wednesday 10:20-11:50 |
| I-096 Yin Edwards Pharmacokinetics/pharmacodynamics and exposure-response modelling of VH3810109 (N6LS) in antiretroviral therapy-naïve adults with HIV-1 from the Phase IIa BANNER Study Wednesday 10:20-11:50 |
| I-103 Aneeq Farooq A pharmacometric model assessing the synergistic effect of bacteriophage-polymyxin combination therapy in a clinical multidrug-resistant K. pneumoniae isolate in vitro. Wednesday 10:20-11:50 |
| I-116 María García-Cremades Predictors of treatment outcomes in children with rifampicin-resistant tuberculosis: a global individual patient data meta-analysis Wednesday 10:20-11:50 |
| II-015 Silvia Grandoni Do differences in PK defeat similarities in immune system in non-human primates? Pharmacokinetic modelling of standard of care antitubercular drugs in marmosets Wednesday 15:20-16:50 |
| II-016 Meng Gu Evaluating empirical dose-response relationships and dosing strategies of bacteriophage therapy using a mechanism-based modeling approach Wednesday 15:20-16:50 |
| II-026 Felix Hammann Informing BOHEMIA cluster randomized controlled trial ivermectin dose selection in healthy participants in Kenya Wednesday 15:20-16:50 |
| II-028 Miriam Happ Quantifying the impact of infection on murine antibiotic exposure in the framework of non-conventional treatment modalities within the FAIR study Wednesday 15:20-16:50 |
| II-035 Rasmus Henninger Preclinical population pharmacokinetic modelling of skin target site exposure of DNDI-0690 and DNDI-6148 in the treatment of cutaneous leishmaniasis Wednesday 15:20-16:50 |
| II-050 Marjorie Imperial Step-Wise Population Pharmacokinetic Modeling Approach to Characterize Complex Absorption of Lenacapavir Following SC Administration in Healthy Participants Wednesday 15:20-16:50 |
| II-054 Van der Feltz Isabella Delpazolid population pharmacokinetics and pharmacodynamics in patients with pulmonary tuberculosis Wednesday 15:20-16:50 |
| II-065 Woojin Jung Predicting lung exposure of intramuscular niclosamide as an antiviral agent against COVID-19 using power-law-based pharmacokinetic modeling Wednesday 15:20-16:50 |
| II-072 Allan Kengo Population pharmacokinetic analysis of the drug interaction between ritonavir-boosted atazanavir and rifampicin Wednesday 15:20-16:50 |
| II-078 Simon Koele Population pharmacokinetics and exposure-response of BTZ-043 for the treatment of tuberculosis. Wednesday 15:20-16:50 |
| II-090 Anna Largajolli Clinical Model-Based Meta-Analysis applied to Vaccine Development for SARS-CoV-2 Variants Wednesday 15:20-16:50 |
| II-095 Donghwan Lee Beyond One-Size-Fits-All: Tailoring Teicoplanin Regimens for Normal Renal Function Patients with Population Pharmacoki-netics and Monte-Carlo Simulation Wednesday 15:20-16:50 |
| II-103 Yu-Jou Lin Model-informed once-daily dosing strategy for children, adolescents and adults for bedaquiline and delamanid Wednesday 15:20-16:50 |
| II-109 Xuanlin Liu Viral dynamic modeling of nirmatrelvir against SARS-CoV-2 in an in vitro infection model Wednesday 15:20-16:50 |
| III-027 Laurynas Mockeliunas Model-based assessment of early bactericidal activity of rifampicin in combination with meropenem plus amoxicillin/clavulanate among adults with rifampicin-resistant pulmonary tuberculosis Thursday 09:50-11:20 |
| III-032 Felix Müller Understanding variability in microdialysis measurements: introducing a combined calibration approach for piperacillin and tazobactam in LPS-induced septic piglets Thursday 09:50-11:20 |
| III-048 Amaury O'Jeanson Data-driven model selection for model-informed precision dosing: a case study with vancomycin Thursday 09:50-11:20 |
| III-049 Ochuko Orherhe Pharmacometric modelling to describe pharmacokinetics and exposure-response of ivermectin in adolescent patients infected with Trichuris trichiura Thursday 09:50-11:20 |
| III-072 Anh Duc Pham Population plasma and tissue pharmacokinetics of linezolid in healthy volunteers and septic patients Thursday 09:50-11:20 |
| III-087 Quentin Renou External evaluation of a population pharmacokinetic (POP-PK) model of Cabotegravir HIV-1-infected patients treated with long-acting Cabotegravir/Rilpivirine (LA CAB-RPV) Thursday 09:50-11:20 |
| III-088 Juan Eduardo Resendiz Galvan What is the effective concentration of dolutegravir? A pharmacokinetic/pharmacodynamic analysis. Thursday 09:50-11:20 |
| III-109 Raphaël Saporta Pharmacokinetic-pharmacodynamic modelling to characterize the time-course of meropenem effect in vivo on bacteria with high MIC Thursday 09:50-11:20 |
| III-111 Sharon Sawe Population pharmacokinetics of delamanid in adults treated for rifampicin-resistant tuberculosis: effect of pregnancy. Thursday 09:50-11:20 |
| III-113 Carmine Schiavone Understanding Population Heterogeneity in Vaccine-induced Immunity: A Mechanistic Model for Immune Fingerprinting Thursday 09:50-11:20 |
| III-114 Verena Schöning Total and unbound flucloxacillin population pharmacokinetics in patients with Staphylococcus aureus bloodstream infection Thursday 09:50-11:20 |
| III-116 Clarisse Schumer Building a model from comparison of SARS-CoV-2 viral dynamics model proposed since 2020: what are the main differences? Thursday 09:50-11:20 |
| IV-004 Jérémy Seurat Macrophage-induced reduction of bacteriophage density limits the efficacy of pulmonary phage therapy Thursday 15:00-16:30 |
| IV-017 Britta Steffens Pharmacometric analysis to explore moxidectin treatment with and without albendazole in Trichuris trichiura-infected adolescents Thursday 15:00-16:30 |
| IV-020 Oleg Stepanov Utilizing the AZD7442 Model for Accelerated New Drug Development: Pharmacokinetic Insights Across Infectious Disease Prevention and Passive Immunization Thursday 15:00-16:30 |
| IV-063 Alberto Vegas Modelling & simulation of biomarkers during anti-HIV monotherapy treatment Thursday 15:00-16:30 |
| IV-064 Nieves Velez de Mendizabal A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with chronic hepatitis D Thursday 15:00-16:30 |
| IV-066 Bharadwaj Vemparala Modeling the influence of antiretroviral treatment initiation time on post-treatment control of HIV infection Thursday 15:00-16:30 |
| IV-068 Diego Vera-Yunca Assessing clinical outcomes of nosocomial pneumonia patients with a pharmacometric multistate model Thursday 15:00-16:30 |
| IV-073 Jannik Vollmer Combined population PK modelling of cefepime and enmetazobactam to characterize their individual and combined PK from the phase 1 to 3 studies Thursday 15:00-16:30 |
| IV-075 Thanakorn Vongjarudech Evaluation of QT Prolongation During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT) Thursday 15:00-16:30 |
| IV-080 Shayne Watson Population PK and PKPD modeling of TBA-7371 in Healthy Adults and Adults with tuberculosis Thursday 15:00-16:30 |
| IV-088 Francis Williams Ojara Population pharmacokinetic characterisation of plasma-to-breast milk transfer of lamivudine and subsequent infant exposure through breast milk Thursday 15:00-16:30 |
| IV-104 Hinojal Zazo Gómez Dosing evaluation of ceftazidime/avibactam in intensive care unit patients based on pharmacokinetic-pharmacodinamic (PK/PD) modelling and simulation. Thursday 15:00-16:30 |
